Gender disparities in medical care may be compromising cardiovascular outcomes for women with complex metabolic conditions. Despite facing more advanced disease stages, women receive substantially less evidence-based treatment than men for conditions affecting the heart, kidneys, and metabolism simultaneously.
Analysis of nearly 19,000 participants across three major clinical trials reveals that women with cardiovascular-kidney-metabolic syndrome were significantly more likely to present with Stage 4 disease—the most severe classification—yet paradoxically received fewer proven therapies. Women were less frequently prescribed aspirin, statins, renin-angiotensin system inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists compared to men, despite similar or higher risk profiles. The treatment gap persisted even after accounting for age differences and disease severity markers like albumin levels.
This pattern reflects a troubling disconnect in cardiovascular medicine, where women historically receive less aggressive treatment despite equal or greater disease burden. The cardiovascular-kidney-metabolic syndrome represents a convergence of conditions—diabetes, chronic kidney disease, and heart failure—that disproportionately affects aging populations and requires coordinated, intensive management across multiple organ systems.
The findings challenge current clinical practice patterns and suggest that standard risk assessment tools may inadequately capture women's cardiovascular vulnerability. While both sexes experienced similar rates of heart failure hospitalization and cardiovascular death over nearly three years of follow-up, the persistent treatment disparities raise questions about whether optimal outcomes are being achieved. This represents more than statistical variance—it suggests systematic under-recognition of cardiovascular risk in women with metabolic comorbidities, potentially contributing to preventable morbidity in this population.